Compare PHAT & SSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAT | SSII |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2019 | N/A |
| Metric | PHAT | SSII |
|---|---|---|
| Price | $12.78 | $3.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.33 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 112.0K |
| Earning Date | 03-05-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $147,190,000.00 | $36,066,457.00 |
| Revenue This Year | $221.87 | N/A |
| Revenue Next Year | $80.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 460.30 | 158.36 |
| 52 Week Low | $2.21 | $3.02 |
| 52 Week High | $18.31 | $22.42 |
| Indicator | PHAT | SSII |
|---|---|---|
| Relative Strength Index (RSI) | 38.22 | 36.10 |
| Support Level | $12.22 | $3.40 |
| Resistance Level | $14.53 | $6.01 |
| Average True Range (ATR) | 0.85 | 0.55 |
| MACD | -0.12 | -0.10 |
| Stochastic Oscillator | 23.22 | 25.25 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.